Focus: Merit Medical is a public medical device company with $1.3B in revenue serving multiple therapeutic areas including cardiovascular, oncology, nephrology, ophthalmology, and neurology. The 5,000+ employee organization manufactures specialized interventional and surgical devices across a diversified portfolio.
Profile data last refreshed 53m ago · AI intelligence enriched 1mo ago
Hot — 226 jobs added in 30d
Net +171 (226 new, 55 removed). Aggressive expansion phase.
Merit Medical is a stable, cash-generative device company suited for careers in commercialization and manufacturing operations, but offers limited exposure to clinical development and early-stage innovation.
Help build intelligence for Merit Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Merit Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Merit Medical Systems, Inc. (MMSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merit Medical Systems, Inc. (MMSI) Stock Price, News, Quote & History Yahoo! Finance Canada
Merit Medical Systems, Inc. (MMSI) stock price, news, quote and history - Yahoo Finance Australia
Merit Medical Systems, Inc. (MMSI) stock price, news, quote and history Yahoo Finance Australia
ESMO Readouts Steal the Spotlight, These Three Oncology Stocks Don’t Need the Podium - NAI500
ESMO Readouts Steal the Spotlight, These Three Oncology Stocks Don’t Need the Podium NAI500
837 MBBS Seats Vacant After NEET 2026 Counselling: Fee Crisis Explained - medadmit.in
837 MBBS Seats Vacant After NEET 2026 Counselling: Fee Crisis Explained medadmit.in
BFUHS NEET PG 2026 NRI Merit List: Round 1 Counselling - medadmit.in
BFUHS NEET PG 2026 NRI Merit List: Round 1 Counselling medadmit.in
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? - TradingView
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Patency rates following treatment with the WRAPSODY™ Cell-Impermeable Endoprosthesis for recalcitrant renal access circuit dysfunction: Results from a tertiary Australian centre.
Objective Performance Goals Based on a Systematic Review and Meta-Analysis of Clinical Outcomes for Bare-Metal Stents and Percutaneous Transluminal Angioplasty for Hemodialysis-Related Central Venous Obstruction.
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo